Covid-19 Clinical Trial
— MY-CO-VIDOfficial title:
Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU
Verified date | March 2021 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
Status | Completed |
Enrollment | 576 |
Est. completion date | February 23, 2021 |
Est. primary completion date | February 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria : - ICU patients COVID-19 diagnosed by RT-PCR - Intubated and mechanically ventilated patients - Adult patients - Patients (or legal representative) informed on the research without opposition Non-inclusion criteria : - Patients <18 years old - People of full age who are the subject of a judicial safeguard, Exclusion criteria: - Patient, or legal representative opposing the pursuit of the research - Patients under judicial protection will be excluded as soon as the investigator becomes aware of their status. |
Country | Name | City | State |
---|---|---|---|
France | CHU Angers | Angers | |
France | CHU de Brest | Brest | |
France | CHU de Dijon | Dijon | |
France | CHU Grenoble | Grenoble | |
France | CHU Lille | Lille | |
France | CHU Lyon | Lyon | |
France | CHU Marseille | Marseille | |
France | CHU Nantes | Nantes | |
France | CHU de Nice | Nice | |
France | CHU Paris - Avicenne | Paris | |
France | CHU Paris - Bichat | Paris | |
France | CHU Paris - HEGP | Paris | |
France | CHU Paris - Mondor | Paris | |
France | CHU Paris - Tenon | Paris | |
France | Hôpital Lariboisière/ St Louis | Paris | |
France | Hôpital Necker-Enfants Malades | Paris | |
France | Hôpital Pitié-Salpêtrière | Paris | |
France | CHU Poitiers | Poitiers | |
France | CHU Rennes | Rennes | |
France | CHU Strasbourg | Strasbourg | |
France | CHU Toulouse | Toulouse | |
France | CHU Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Opportunistic fungal co-infections. | Prevalence of opportunistic fungal co-infections. | at 12 months | |
Secondary | Median time | Determination of the median time between entry in ICU and beginning of ARDS and (i) colonization and (ii) probable/proven infection with Aspergillus, Pneumocystis jirovecii and mucormycetes | at 12 months | |
Secondary | Time between diagnosis and targeted treatment | Evaluation of the time between diagnosis and targeted treatment | at ICU discharge, up to 1 month | |
Secondary | Preventive strategies | Number of proposals for evaluation of preventive strategies if necessary, because of high incidence, in terms of chemoprophylaxis and/or environmental measures | At 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|